Can Neurogenomics Contribute to Better Neurotherapy?
Wednesday, May 18, 2005 WALTHAM, Mass., May 18 /PRNewswire/ — CNS disorders affect a vast patient population and represent a huge area of unmet therapeutic need. In the United States alone, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis afflict more than 6.5 million people. The complexity of CNS diseases make this a challenging but potentially very rewarding area for research. A new CHA Advances Report, Neurogenomics and Neurotherapeutic Strategies: New Directions in Platforms, Targets, and Therapeutic Approaches evaluates emerging drug development efforts in this arena, focusing on six major CNS diseases: Alzheimer’s Disease Parkinson’s Disease Amyotrophic Lateral Sclerosis Schizophrenia Depression Bipolar Disorder According to the CHA report, the role of neurogenomics in the future development of neurology and neuropsychiatry therapy markets will be that of a significant behind-the-scenes player at the discovery and preclinical level: * It will contribut
